Key facts
- Avisi (Therapeutic Devices)’s last known valuation is $40.0M (Feb 2026).
- It has raised $21.7M; the latest was Later Stage VC ($15.9M) in Feb 2026.
- Notable investors include US National Science Foundation, MedTech Innovator, Gaingels, Keiretsu Forum, VentureWell — 35 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 35 names
- ·Watchlist + deal alerts for Avisi (Therapeutic Devices)
- ·The full record, as it builds
Funding rounds
No funding rounds for Avisi (Therapeutic Devices) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avisi (Therapeutic Devices)
Developer of a nanotechnology-enabled glaucoma implant designed to lower intraocular pressure and slow vision loss in patients with open-angle glaucoma. The company offers an ultrathin multichannel aqueous shunt made with advanced microfabrication and biocompatible materials, enabling ophthalmologists and glaucoma patients to achieve controlled fluid drainage and improved long-term eye health.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2017
- Employees
- 7
- Website
- avisitech.com/
- Ownership
- Privately Held (backing)
Avisi (Therapeutic Devices) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avisi (Therapeutic Devices) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avisi (Therapeutic Devices) in its N-PORT filings yet. We sweep new filings monthly.